Serum Human Epididymis Protein 4 as a Prognostic Marker in Cervical Cancer

Woo Yeon Hwang, MD1,2, Dong Hoon Suh, MD, PhD1,2, Kidong Kim, MD, PhD1,2, Yong Beom Kim, MD, PhD1,2, and Jae Hong No, MD, PhD1,2

Abstract

Objectives: The objective is to evaluate the prognostic value of serum human epididymis protein 4 (HE4) as a tumor marker in patients with cervical cancer.

Methods: Sixty-seven patients with cervical cancer treated at Seoul National University Bundang Hospital from September 2014 to May 2018 were retrospectively reviewed. Serum HE4 levels were measured by immunoassay before starting primary treatment. A mean serum HE4 level of 72.6 pmol/L was used to divide the patients into low and high HE4 groups. Patient characteristics, clinicopathological variables, and survival outcomes were compared between the two groups.

Results: The low and high HE4 groups included 55 (82.1%) and 12 (17.9%) patients at diagnosis, respectively. Higher HE4 levels were significantly associated with older age at diagnosis (age <50: 0% vs age ≥50: 100.0%; P = .002), menopause (premenopause: 8.3% vs postmenopause: 91.7%; P = .009), higher FIGO stage (stage I–II: 33.3% vs III–IV: 66.7%; P = .017), large tumor size (<4.0 cm: 41.7% vs ≥4.0 cm: 58.3%; P = .029), positive lymph node metastasis (negative: 41.7% vs positive: 58.3%; P = .049), and involvement of the parametrium (negative: 25.0% vs positive: 75.0%; P = .002). Higher HE4 level was a predictive factor for worse overall survival but not for progression-free survival. Elevated HE4 levels were not independent factors for the prediction of either overall survival or progression-free survival. Subgroup analysis by histological type revealed similar results for patients with squamous cell carcinoma.

Conclusions: High levels of HE4 expression correlated with poor overall survival, indicating that elevated HE4 levels are associated with a poor prognosis for patients with cervical cancer.

Keywords

human epididymis protein 4, cervical cancer, tumor marker, prognosis, survival

Received September 27, 2021. Received revised March 14, 2022. Accepted for publication April 8, 2022.

Introduction

Over the past few decades, efforts have been made to reduce the incidence and mortality of cervical cancer through early detection and prevention. Nevertheless, cervical cancer remains the fourth most commonly diagnosed cancer and the fourth leading cause of cancer-related death in women worldwide.1 Histologically, approximately 80% of cervical cancer cases are that of squamous cell carcinoma (SCC) and approximately 20% are that of adenocarcinoma (ADC).2,3 Currently, squamous cell carcinoma antigen (SCC-Ag) and cancer antigen 125 (CA 125) are the most used...
tumor markers for cervical cancer. However, increased levels of SCC-Ag are present in only 64% of patients with SCC and 25% of patients with ADC, while increased levels of CA 125 are present in only 42.6% of patients with SCC and in 18.9% of patients with ADC. Therefore, the identification of novel markers that improve the detection rate of cervical cancer is required.

Cervical cancer is a preventable disease, and its morbidity and mortality has been dramatically reduced by the introduction of cervical cytology. However, cervical cytology has low sensitivity and a high false positive rate, partially due to inadequate specimen collection. Adjunctive tests such as colposcopy and screening for human papillomavirus (HPV) have been suggested to overcome this low accuracy. In addition, tumor markers for the diagnosis and follow up of cervical cancer are necessary. SCC-Ag is the most widely used tumor marker in the diagnosis of cervical cancer. Elevated levels of SCC-Ag are related to tumor size and stage of disease before treatment, as well as to the response to treatment. However, the diagnostic sensitivity is only 30% for early cervical cancer. Further, the utility of SCC-Ag in other histologic types remains unclear. These limitations demonstrate the importance of identifying other tumor markers for cervical cancer.

Human epididymis protein 4 (HE4) is a promising biomarker that has been shown to have great potential for clinical use. HE4 was first isolated from the epithelial cells of the human epididymis and can also be detected in serum. HE4 expression has also been identified in normal human tissues outside of the male reproductive system, as well as in various types of malignancies. Previous studies have demonstrated that HE4 levels are higher in tumors of gynecologic origin, and HE4 is well established in ovarian and endometrial cancers. It has been reported that serum HE4, both alone and in combination with CA 125, has great potential to predict prognosis. Based on previous studies in ovarian cancer cells, the biological role of HE4 in malignant cells is controversial. One study reported that HE4 could inhibit cell proliferation by regulating the MAPK PI3K/AKT pathway. Meanwhile, other studies reported that HE4 promotes proliferation, invasion, and metastasis of ovarian cancer cells. Additionally, in another study, knockdown of HE4 mediated the reduced cell proliferation, invasion, migration and tumor growth, and increased apoptosis through inhibiting of the JAK/STAT3 pathway.

Although it is known that serum levels of HE4 are significantly increased in ovarian and endometrial cancers, research on cervical cancer has been minimal. A tumor marker that enables better stratification of patients with cervical cancer may improve individualized primary treatment and help prevent over- or under-treatment of these patients. Therefore, we sought to evaluate the prognostic value of serum HE4 as a tumor marker for cervical cancer patients.

Methods
This retrospective study received approval from the Institutional Review Board of the Seoul National University Bundang Hospital (SNUBH; No. B-1602/336-103) and was performed in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study.

We retrospectively reviewed the medical records of 67 patients with cervical cancer who were treated at Seoul National University Bundang Hospital, a tertiary hospital in Korea, from September 2014 to May 2018. All patients were restaged based on the revised 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer. We included patients who met the following inclusion criteria: (1) patients who had histologically confirmed cervical cancer of any stage; (2) those who underwent initial treatment, such as radical hysterectomy with lymphadenectomy, concurrent chemoradiation therapy, radiation therapy or chemotherapy only; and (3) those who had HE4 levels assessed at diagnosis, before initiation of first treatment. Patients were excluded if they had: (1) incomplete treatment for any reason; (2) insufficient clinical and pathological data; (3) other malignancies that had the potential to influence survival outcomes; and (4) a history of renal failure or creatinine $\geq 1.5$ mg/dL.

The medical records, surgical records, pathological findings, and clinical characteristics of included patients were reviewed. Histology was pathologically evaluated in all patients. Tumor size, lymphovascular space invasion (LVSI), lymph node (LN) metastasis, and involvement of the parametrium (PM) were evaluated pathologically only in patients who initially received surgery, while magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography computed tomography were evaluated in patients who received initial treatment other than surgery.

The serum HE4 concentration was measured before initiation of patient treatment using the Architect Analyzer (Abbott Laboratories, USA). This is a two-step immunoassay that quantitatively measures HE4 levels in human serum using chemiluminescent microparticle technology. The inter-assay precision for measurement of HE4 was 3.5% (49.7 pmol/L), 3.6% (168.1 pmol/L), and 3.8% (648.2 pmol/L).

The mean serum HE4 level prior to the initiation of treatment of the 67 included patients were 72.6 pmol/L (standard deviation = 95.0). We evaluated the differences in clinicopathological characteristics between patients with lower (<72.6 pmol/L) and higher ($\geq$72.6 pmol/L) HE4 levels at initial diagnosis.

Statistical Analysis
For comparison of continuous variables, the Student’s $t$-test and Mann–Whitney $U$ test were used. Ordinal and categorical variables were analyzed using Pearson’s chi-squared test or Fisher’s exact test, as applicable. The association between HE4 levels and the survival outcomes of patients with cervical cancer was assessed by comparing patients with lower HE4 levels (<72.6 pmol/L) and those with higher HE4 levels ($\geq$72.6 pmol/L) before the start of treatment. Progression-free survival (PFS) and overall survival (OS) rates were calculated by the Kaplan–Meier method and the differences between curves were assessed using the log-rank test. Univariate analysis was
Table 1. Characteristics of the overall study population (N = 67).

| Characteristic                  | n (%)          | Death          |   |   |   |
|--------------------------------|----------------|----------------|---|---|---|
|                                |                | No (n = 55)    | Yes (n = 12) |   | P value |
| Age, years                     | 53.4 ± 13.2    | 51.3 ± 12.0    | 62.8 ± 15.0  |   | .006a   |
| Mean ± SD                      |                |                |              |   |         |
| Menopause                      |                |                |              |   |         |
| No                             | 28 (41.8)      | 26 (47.3)      | 2 (16.7)     |   | .051b   |
| Yes                            | 39 (58.2)      | 29 (52.7)      | 10 (83.3)    |   |         |
| Creatinine, mg/dL              | .7 ± 0.2       | .7 ± 0.2       | .9 ± 0.2     |   | .013a   |
| Histology                      |                |                |              |   |         |
| Squamous cell carcinoma        | 50 (74.6)      | 41 (74.5)      | 9 (75.0)     |   | .171b   |
| Adenocarcinoma                 | 15 (22.4)      | 13 (23.6)      | 2 (16.7)     |   |         |
| Adenosquamous cell carcinoma   | 1 (1.5)        | 0 (0)          | 1 (8.3)      |   |         |
| Others                         | 1 (1.5)        | 1 (1.8)        | 0 (0)        |   |         |
| FIGO stage                     |                |                |              |   | <.001b  |
| I                              | 40 (59.7)      | 39 (70.9)      | 1 (8.3)      |   |         |
| II                             | 4 (6.0)        | 3 (5.5)        | 1 (8.3)      |   |         |
| III                            | 17 (25.4)      | 11 (20.0)      | 6 (50.0)     |   |         |
| IV                             | 6 (9.0)        | 2 (3.6)        | 4 (33.3)     |   |         |
| Tumor size, cm                 |                |                |              |   | <.001c  |
| <4.0                           | 48 (71.6)      | 45 (81.8)      | 3 (25.0)     |   |         |
| ≥4.0                           | 19 (28.4)      | 10 (18.2)      | 9 (75.0)     |   |         |
| LVSI                           |                |                |              |   | <.001b  |
| Negative                       | 27 (40.3)      | 27 (49.1)      | 0 (0)        |   |         |
| Positive                       | 18 (26.9)      | 17 (30.9)      | 1 (8.3)      |   |         |
| Unknown                        | 22 (32.8)      | 11 (20.0)      | 11 (91.7)    |   |         |
| LN metastasis                  |                |                |              |   | .014c   |
| Negative                       | 45 (67.2)      | 41 (74.5)      | 4 (33.3)     |   |         |
| Positive                       | 22 (32.8)      | 14 (25.5)      | 8 (66.7)     |   |         |
| PM involvement                 |                |                |              |   | .021c   |
| Negative                       | 43 (64.2)      | 39 (70.9)      | 4 (33.3)     |   |         |
| Positive                       | 24 (35.8)      | 16 (29.1)      | 8 (66.7)     |   |         |
| Initial treatment              |                |                |              |   | <.001b  |
| Operation                      | 45 (67.2)      | 43 (78.2)      | 2 (16.7)     |   |         |
| CCRT                           | 16 (23.9)      | 11 (20.0)      | 5 (41.7)     |   |         |
| RTx                            | 2 (3.0)        | 0 (0)          | 2 (16.7)     |   |         |
| CTx                            | 4 (6.0)        | 1 (1.8)        | 3 (25.0)     |   |         |
| Adjuvant treatment             |                |                |              |   | .014b   |
| No                             | 29 (43.3)      | 35 (63.6)      | 3 (25.0)     |   |         |
| Yes                            | 38 (56.7)      | 20 (36.4)      | 9 (75.0)     |   |         |
| Recurrence                     |                |                |              |   | <.001c  |
| No                             | 15 (22.4)      | 49 (89.1)      | 3 (25.0)     |   |         |
| Yes                            | 52 (77.6)      | 6 (10.9)       | 9 (75.0)     |   |         |
| Death                          |                |                |              |   |         |
| No                             | 55 (82.1)      | -              | -            |   |         |
| Yes                            | 12 (17.9)      | -              | -            |   |         |

Data are mean ± SD or N (%) unless otherwise specified.
Abbreviations: SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; CCRT, concurrent chemoradiation therapy; RTx, radiation therapy; CTx, chemotherapy.

aP values were calculated by Student’s t-test.
bP values were calculated by Pearson’s chi-squared test.
cP values were calculated by Fisher’s exact test.
performed using the Cox proportional hazards model to evaluate the impact of patient characteristics and clinical factors on survival. For multivariate survival analysis, Cox proportional hazards analysis was used to estimate the prognostic effects of several variables. All analyses were performed using SPSS software for Windows (version 25.0; SPSS Inc., Chicago, IL, USA). P<.05 indicated statistical significance.

### Results

The overall patient characteristics of the 67 included patients are presented in Table 1. The mean age of the population was 53.4 ± 13.2 years. There were 28 (41.8%) premenopausal patients and 39 (58.2%) postmenopausal patients. The value of baseline creatinine level was .7 ± .2 mg/dL. The most common histological type was SCC (74.6%), followed by ADC (22.4%), adenosquamous cell carcinoma 1 (1.5%), and others (1.5%). A total of 40 (59.7%) patients were stage I, 4 (6.0%) patients were stage II, 17 (25.4%) patients were stage III, and 6 (9.0%) patients were stage IV. The size of tumor was less than 4 cm in 71.6% and more than 4 cm in 28.4%. A higher proportion of patients had negative results of LVSI, LN metastasis, and PM involvement (LVSI, 40.3%; LN metastasis, 67.2%; PM involvement 64.2%). Over half of the patients underwent surgery (67.2%) for primary treatment, and 29 (43.3%) had adjuvant treatment after initial

| Characteristic         | HE4 <72.6 pmol/L (n = 55) | HE4 ≥72.6 pmol/L (n = 12) | P value |
|------------------------|---------------------------|---------------------------|---------|
| Age, years             |                           |                           | .002b   |
| <50                    | 26 (47.3)                 | 0 (.0)                    |         |
| ≥50                    | 29 (52.7)                 | 12 (100.0)                |         |
| Menopause              |                           |                           | .009a   |
| No                     | 27 (49.1)                 | 1 (8.3)                   |         |
| Yes                    | 28 (50.9)                 | 11 (91.7)                 |         |
| Histology              |                           |                           | .270h   |
| Squamous cell carcinoma| 39 (70.9)                 | 11 (91.7)                 |         |
| Non-squamous cell carcinoma | 16 (29.1)      | 1 (8.3)                   |         |
| FIGO stage             |                           |                           | .017b   |
| I-II                   | 40 (72.7)                 | 4 (33.3)                  |         |
| III-IV                 | 15 (27.3)                 | 8 (66.7)                  |         |
| Tumor size, cm         |                           |                           | .029b   |
| <4.0                   | 43 (78.2)                 | 5 (41.7)                  |         |
| ≥4.0                   | 12 (21.8)                 | 7 (58.3)                  |         |
| LVSI                   |                           |                           | .003a   |
| Negative               | 25 (45.5)                 | 2 (16.7)                  |         |
| Positive               | 17 (30.9)                 | 1 (8.3)                   |         |
| Unknown                | 13 (23.6)                 | 9 (75.0)                  |         |
| LN metastasis          |                           |                           | .049b   |
| Negative               | 40 (72.7)                 | 5 (41.7)                  |         |
| Positive               | 15 (27.3)                 | 7 (58.3)                  |         |
| PM involvement         |                           |                           | .002b   |
| Negative               | 40 (72.7)                 | 3 (25.0)                  |         |
| Positive               | 15 (27.3)                 | 9 (75.0)                  |         |
| Adjuvant treatment     |                           |                           | .604a   |
| No                     | 32 (58.2)                 | 6 (50.0)                  |         |
| Yes                    | 23 (41.8)                 | 6 (50.0)                  |         |
| Recurrence             |                           |                           | .721h   |
| No                     | 42 (76.4)                 | 10 (83.3)                 |         |
| Yes                    | 13 (23.6)                 | 2 (16.7)                  |         |
| Death                  |                           |                           | .032b   |
| No                     | 48 (87.3)                 | 7 (58.3)                  |         |
| Yes                    | 7 (12.7)                  | 5 (41.7)                  |         |

Data are N (%) unless otherwise specified.

Abbreviations: HE4, human epididymis protein 4; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; LN, lymph node; PM, parametrium.

aP values were calculated by Pearson’s chi-squared test.
bP values were calculated by Fisher’s exact test.
therapy regardless of the type of primary treatment. During a median length of observation of 43.8 months (range: 9.2–60.9 months), 11 patients (16.4%) experienced disease recurrence and 12 patients (17.9%) died. In addition, we compared the data according to death. Death was significantly associated with older age at diagnosis (P = .006) but not with menopause (P = .051). Higher level of creatinine was associated with death (P = .013); however, it was within the normal range. Higher FIGO stage (P < .001), tumor size (P < .001), LVSI (P < .001), LN metastasis (P = .014), PM involvement (P = .021), type of initial treatment (P < .001), more adjuvant treatment (P = .014), and higher recurrence (P < .001) were also associated with death. Meanwhile, the histologic type was no significantly associated with death (P = .171).

The mean concentration of serum HE4 was used to discriminate between low and high HE4 levels. There were 55 (82.1%) patients with mean HE4 levels below 72.6 pmol/L and 12 (17.9%) patients with mean HE4 levels above 72.6 pmol/L at the date of diagnosis. Higher HE4 levels were significantly associated with older age at diagnosis (P = .002), menopause (P = .009), higher FIGO stage (P = .017), larger tumor size (P = .029), presence of LVSI (P = .003), positive LN metastasis (P = .049), and involvement of the PM (P = .002) (Table 2). There was no statistically significant association between HE4 and histology (P = .270), adjuvant treatment (P = .604), or recurrence (P = .721), while there was statistically significant association between HE4 and death (P = .032). We additionally analyzed according to the median HE4, 47.3 pmol/L (range: 28.8–569.8 pmol/L) to adjust the study population imbalance between the two groups, but the results did not appear to be significant (Supplemental Table S1).

Figure 1 shows the PFS and OS of patients in each group. There was no significant difference in PFS between the two groups (hazard ratio [HR]: .650; 95% confidence interval [CI]: .145–2.921; P = .572) (Figure 1(A)). However, patients with higher HE4 levels had significantly worse OS than those with lower HE4 levels (HR: 3.726; 95% CI: 1.182–11.747; P = .016) (Figure 1(B)). We also performed subgroup analysis of patients with the SCC histological type (N = 50), and the results were consistent with those of the overall study population. There was no significant difference observed in PFS (HR: .974; 95% CI: .198–4.805; P = .975) (Figure 1(C)), but patients with higher HE4 levels were associated with worse OS than those with lower HE4 levels (HR: 5.449; 95% CI: 1.460–20.332; P = .005) (Figure 1(D)).

To assess the prognostic significance of clinicopathological variables on PFS and OS, we performed univariate Cox analysis. FIGO stage, tumor size, LN metastasis, and

Figure 1. Comparisons of survival outcomes between patients with low (<72.6 pmol/L) and high (≥72.6 pmol/L) HE4. (A) Progression-free survival in the entire cohort; (B) overall survival in the entire cohort; (C) progression-free survival in patients with squamous cell carcinoma; and (D) overall survival in patients with squamous cell carcinoma.
involvement of the PM were identified as unfavorable factors for PFS and OS (Table 3). In addition, higher HE4 levels were significantly associated with poor clinical outcomes for OS (HR: 3.726; 95% CI: 1.182–11.747; P = .025; Table 3). On multivariate analysis, higher HE4 levels did not remain as an independent indicator of OS (HR: 1.621; 95% CI: .412–6.371; P = .489; Table 3). The results were similar in the subgroup analysis for the SCC histological type. Univariate analysis revealed that high levels of HE4 were associated with poor OS (HR: 5.449; 95% CI: 1.460–20.332; P = .012; Table 4), whereas multivariate analysis revealed that high levels of HE4 did not influence OS (HR: 2.856; 95% CI: .663–12.294; P = .159; Table 4).

### Discussion

In this study, we found that high expression of HE4 is correlated with poor OS, indicating that HE4 is a potential candidate biomarker for predicting the prognosis of cervical cancer. Our findings revealed that, in cervical cancer patients, elevated serum HE4 levels were significantly correlated with FIGO stage as well as tumor size, LVSI, LN metastasis, and PM involvement but not with histological type. Moreover, we found that in univariate analysis, serum HE4 levels were associated with worse OS. However, HE4 levels were not found to be an independent prognostic factor for PFS. Similar results were observed in the subgroup analysis of patients with histologically confirmed SCC.

Previous studies regarding serum HE4 as a biomarker in cervical cancer are limited. Some studies have shown that patients with cervical cancer may also have higher levels of HE4. However, as these studies were limited by their small sample size, it remains unclear whether HE4 is a valuable marker for cervical cancer. A more recent study evaluating the role of pre-treatment serum HE4 levels in cervical cancer reported that serum HE4 could be a preoperative tumor biomarker of poor prognosis in cervical cancer. Consistent with our own results, this study also demonstrated that higher levels of serum HE4 correlate with advanced stage, larger tumor size, and high tumor grade, while no significant association was found with LVSI, PM involvement, and LN involvement, which is not consistent with our study.

Careful attention is required in interpreting serum HE4 levels as they can be affected by numerous factors. Previous studies have shown that age, menopausal status, smoking, renal function, chronic liver disease, ethnicity, and detection method may influence serum HE4 levels. Thus, our results should be interpreted with caution. Currently, there is no consensus established for optimal baseline serum HE4 cutoff values. According to previous published investigations, a serum HE4 cut-off

### Table 3. Factors associated with survival in the overall population.

| Variables          | Progression-free survival | Overall survival |
|--------------------|----------------------------|-----------------|
|                    | Univariate analysis | HR | 95% CI | P value | Multivariate analysis | HR | 95% CI | P value | Univariate analysis | HR | 95% CI | P value | Multivariate analysis | HR | 95% CI | P value |
| Menopause          |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| No                 |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| Yes                | 2.108 .670–6.626         | 3.695 .809–16.871 | .092 | .944 | .954 .258–3.525 | .019 |
| Histologic type    |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| Non-SCC            | .459 .163–1.294         | .954 .258–3.525 |     |       |          |     |
| SCC                | .141                      | .944 | .019 | .232 | .321 .050–2.074 |    |
| FIGO stage         |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| I–II               | .002 .745                 | .001 | .019 | .947 | .321 .050–2.074 | .489 |
| III–IV             | 6.475 2.037–20.576        | 1.663 .078–35.537 | 11.875 2.595–54.334 | 15.186 1.551–148.702 |     |       |          |                           |     |       |          |                           |     |       |          |
| Tumor size         |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| <4.0 cm            | .014 .285                 | .001 | .110 | .232 | .321 .050–2.074 | .489 |
| ≥4.0 cm            | 3.603 1.301–9.981         | 1.896 .587–6.130 | 9.738 2.619–36.201 | 3.583 .748–17.160 |     |       |          |                           |     |       |          |                           |     |       |          |
| LN metastasis      |                           | .001 | .410 | .232 | .321 .050–2.074 | .489 |
| No                 |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| Yes                | 6.516 2.054–20.669        | 3.464 .181–66.338 | 4.707 1.416–15.650 | .321 .050–2.074 |     |       |          |                           |     |       |          |                           |     |       |          |
| PM involvement     |                           | .031 | .830 | .019 | .943 .168–5.302 |    |
| No                 |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| Yes                | 3.144 1.113–8.879         | .868 .239–3.151 | 4.213 1.267–14.010 | .943 .168–5.302 |     |       |          |                           |     |       |          |                           |     |       |          |
| HE4                |                           | .575 | .025 | .489 | .321 .050–2.074 |    |
| <72.6              |                           |     |       |          |                           |     |       |          |                           |     |       |          |                           |     |       |          |
| ≥72.6              | .650 .145–2.921           | 3.726 1.182–11.747 | 1.621 .412–6.371 |     |       |          |                           |     |       |          |                           |     |       |          |

Abbreviations: HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; PM, parametrium; HE4, human epididymis protein 4.
value of 70 pmol/L yields the best sensitivity and specificity. The positive serum HE4 cut-off values previously identified in ovarian and endometrial cancer patients were similar to the mean value of HE4 in our study. In other previous studies, serum HE4 levels were higher in cervical cancer patients compared to healthy controls, but lower than ovarian cancer patients, showing similar results to our study.

This study has several limitations. First, the existence of underlying selection bias is possible due to the retrospective design. Second, the sample size of the study population and the number of recurrence and death events might be insufficient for a comparison of survival outcomes between lower and higher serum HE4 levels. Third, no subgroup analysis was performed for the ADC histology type because of the small sample size of this population. Last, we did not perform power calculations for the estimation of sample size.

Conclusions

In conclusion, our study showed that elevated serum HE4 was associated with poor prognostic factors for cervical cancer and was correlated with poor OS, suggesting the potential of HE4 as a novel biomarker for predicting the survival of patients with cervical cancer.

Appendix

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| ADC | adenocarcinoma |
| CA 125 | cancer antigen 125 |
| CCRT | concurrent chemoradiation therapy |
| CI | confidence interval |
| CT | computed tomography |
| CTx | chemotherapy |
| FIGO | International Federation of Gynecology and Obstetrics |
| HE4 | human epididymis protein 4 |
| HPV | human papillomavirus |
| HR | hazard ratio |
| LN | lymph node |
| LVS1 | lymphovascular space invasion |
| MRI | magnetic resonance imaging |
| OS | overall survival |
| PFS | progression-free survival |
| PM | parametrium |
| RTx | radiation therapy |
| SCC | squamous cell carcinoma |
| SCC-Ag | squamous cell carcinoma antigen |

Table 4. Factors associated with survival in patients with squamous cell carcinoma.

| Variable | Progression-free survival | Overall survival |
|----------|---------------------------|------------------|
|          | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|          | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value |
| Menopause |                |                |        |                |                |        |                |                |        |
| No | 1 |                |        | 1 |                |        | 1 |                |        |
| Yes | 4.901 | .612–39.238 | .134 | 41.687 | .146–11922.202 | .196 |
| FIGO stage |                |                |        |                |                |        |                |                |        |
| I–II | 1 |                |        | 1 |                |        | 1 |                |        |
| III–IV | 6.846 | 1.393–33.642 | .018 | 18.476 | 1.561–218.736 | .021 | 17.443 | 21.178–139.673 | .007 | 20.833 | 1.287–337.164 | .033 |
| Tumor size |                |                |        |                |                |        |                |                |        |
| <4.0 cm | 1 |                |        | 1 |                |        | 1 |                |        |
| ≥4.0 cm | 3.009 | .801–11.297 | .103 | 14.755 | 3.045–71.493 | .061 | 14.755 | 3.045–71.493 | .061 |
| LN metastasis |                |                |        |                |                |        |                |                |        |
| No | 1 |                |        | 1 |                |        | 1 |                |        |
| Yes | 4.203 | 1.024–17.260 | .046 | 14.755 | 3.045–71.493 | .039 | 4.801 | 1.200–19.212 | .027 | 4.801 | 1.200–19.212 | .027 |
| PM involvement |                |                |        |                |                |        |                |                |        |
| No | 1 |                |        | 1 |                |        | 1 |                |        |
| Yes | 2.159 | .573–8.142 | .256 | 3.756 | .939–15.031 | .61 | 3.756 | .939–15.031 | .61 |
| HE4 |                |                |        |                |                |        |                |                |        |
| <72.6 | 1 |                |        | 1 |                |        | 1 |                |        |
| ≥72.6 | 1.026 | .208–5.060 | .975 | 5.449 | 1.460–20.332 | .012 | 5.449 | 1.460–20.332 | .012 |

Abbreviations: HR, hazard ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; PM, parametrium; HE4, human epididymis protein 4.

Acknowledgments

Thanks to all the authors who contributed to this article, and to the publisher for supporting this article.

Authors’ contributions

W Y Hwang, D H Suh, and J H No designed the research of study. W Y Hwang and J H No performed the research. W Y Hwang and J H
No analyzed data. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

**Declaration of conflicting interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Seoul National University Bundang Hospital Research Fund [grant number 02-2014-0048]. The funding source played no role in the study design; the collection, analysis, or interpretation of the data; the writing of the report; or the decision to submit the article.

**Ethics approval and consent to participate**
This retrospective study received approval from the Institutional Review Board of the Seoul National University Bundang Hospital (SNUBH; No. B-1602/336-103) and was performed in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study.

**ORCID iDs**
Woo Yeon Hwang https://orcid.org/0000-0003-0231-8330
Jae Hong No https://orcid.org/0000-0002-2389-6757

**Supplemental Material**
Supplemental material for this article is available online.

**References**
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
2. Couvreur K, Naert E, De Jaeghere E, et al. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. BMC Cancer. 2018;18(1):1101. doi:10.1186/s12885-018-5007-0
3. Laengsri V, Kerdpin U, Plabplueng C, Treeratanapiboon L, Nuchnoi P. Cervical Cancer Markers: Epigenetics and micro-RNAs. Lab Med. 2018;49(2):97-111. doi:10.1093/labmed/lmx080
4. Barut MU, Kale A, Kuyumcuoglu U, et al. Analysis of Sensitivity, Specificity, and Positive and Negative Predictive Values of Smear and Colposcopy in Diagnosis of Premalignant and Malignant Cervical Lesions. Med Sci Mon Int Med J Exp Clin Res. 2015;21:3860-3867. doi:10.12659/msm.895227
5. Boone JD, Erickson BK, Huh WK. New insights into cervical cancer screening. Journal of gynecologic oncology. 2012;23(4):282-287. doi:10.3802/jgo.2012.23.4.282
6. Lim S-C, Yoo CW. Current Status of and Perspectives on Cervical Cancer Screening in Korea. Journal of pathology and translational medicine. 2019;53(4):210-216. doi:10.4132/jptm.2019.04.11
7. Fu J, Wang W, Wang Y, Liu C, Wang P. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 2019;14(1):146. doi:10.1186/s13014-019-1355-4
8. Molina R, Filella X, Augé JM, et al. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anti-cancer Res. 2005;25(3a):1765-1771.
9. Manganaro L, Michienzi S, Vinci V, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013;30(5):2481-2487. doi:10.3892/or.2013.2682
10. Nassir M, Guan J, Luketina H, et al. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. Tumor Biol. 2016;37(3):3009-3016. doi:10.1007/s13277-015-4031-9
11. Kumarasamy C, Madhav MR, Sabarinurugan S, et al. Diagnostic and prognostic role of HE4 expression in multiple carcinomas. Medicine. 2019;98(28):e15336. doi:10.1097/md.0000000000015336
12. Kirchhoff C, Habben I, Ivell R, Krull N. A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors1. Biol Reprod. 1991;45(2):350-357. doi:10.1095/biolreprod45.2.350
13. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21(17):2768-2773. doi:10.1038/sj. onc.1205363
14. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19(6):847-853. doi:10.1038/modpathol.3800612
15. Cymbaluk-Ploska A, Chudecka-Glaz A, Pius-Sadowska E, et al. Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients. Oncotargets Ther. 2017;Volume 10:3169-3175. doi:10.2147/ott.S136750
16. Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol. 2013;209(2):e1-142. doi:10.1016/j.ajog.2013.04.014
17. Molina R, Escudero JM, Augé JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biol. 2011;32(6):1087-1095. doi:10.1007/s13277-011-0204-3
18. Grisaru D, Hauspy J, Prasad M, et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scarpings. Oncol Rep. 2007;18(6):1347-1356.
19. Drapkin R, van Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. *Cancer Research*. 2005;65(6):2162-2169. doi:10.1158/0008-5472.Can-04-3924

20. Kalapotharakos G, Asciutto C, Henic E, Casslén B, Borgfeldt C. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. *J Ovarian Res*. 2012;5(1):20. doi:10.1186/1757-2215-5-20

21. Mutz-Dehbalaie I, Egle D, Fessler S, et al. HE4 is an independent prognostic marker in endometrial cancer patients. *Gynecol Oncol*. 2012;126(2):186-191. doi:10.1016/j.ygyno.2012.04.022

22. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma. *Cancer Res*. 2003;63(13):3695-3700.

23. Kong X, Chang X, Cheng H, Ma R, Ye X, Cui H. Human epididymis protein 4 inhibits proliferation of human ovarian cancer cells via the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways. *Int J Gynecol Cancer*. 2014;24(3):427-436. doi:10.1097/igc.0000000000000078

24. Zhuang H, Hu Z, Tan M, et al. Overexpression of Lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells. *Biochimie*. 2014;105:91-98. doi:10.1016/j.biochi.2014.06.022

25. Zhuang H, Huang H, Wang H, et al. Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. *Oncotarget*. 2016;7(1):729-744. doi:10.18632/oncotarget.6327

26. Wang A, Jin C, Tian X, Wang Y, Li H. Knockdown of HE4 suppresses aggressive cell growth and malignant progression of ovarian cancer by inhibiting the JAK/STAT3 pathway. *Biology open*. 2019;8(9). doi:10.1242/bio.043570

27. Bhatia N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. *Int J Gynecol Obstet*. 2018;143(S2):22-36. doi:10.1002/ijgo.12611

28. Montagnana M, Lippi G, Ruzzene O, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. *J Clin Lab Anal*. 2009;23(5):331-335. doi:10.1002/jcla.20340

29. Bignotti E, Zanotti L, Todeschini P, et al. Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients. *Front Oncol*. 2020;10:584022. doi:10.3389/fonc.2020.584022

30. Simmons AR, Baggerly K, Bast RC Jr. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial cancers. *Oncology*. 2013;27(6):548-556.

31. Tian Y, Wang C, Cheng L, et al. Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women. *J Ovarian Res*. 2015;8(1):72. doi:10.1186/s13048-015-0201-z

32. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. *Gynecol Oncol*. 2009;112(1):40-46. doi:10.1016/j.ygyno.2008.08.031

33. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr., Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. *Am J Obstet Gynecol*. 2012;206(4):e1-349. doi:10.1016/j.ajog.2011.12.028

34. Karlsen NS, Karlsen MA, Høgdall CK, Høgdall EVS. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. *Cancer Epidemiol Biomark Prev*. 2014;23(11):2285-2295. doi:10.1158/1055-9965.Epi-14-0447

35. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. *Br J Cancer*. 2009;100(8):1315-1319. doi:10.1038/sj bj.6605011